CD274 and neoplasm: However, B16F10-GCV mice with anti-PD-L1 treatment showed an improved survival rate compared to isotype Ctrl treated mice 50 days after tumor inoculation and 43 days after starting anti-PDL1 or isotype Ctrl treatment (Figure 2A).